MedTrace Logo

Ticagrelor and Adenosine

NCT01996735 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2014-01-10

No results posted yet for this study

Summary

Preclinical studies have shown that the P2Y12 receptor antagonist ticagrelor can increase the extracellular concentration of the endogenous nucleoside adenosine by inhibiting the cellular uptake of adenosine via the equilibrative nucleoside transporter (ENT). This mechanism can contribute to the beneficial effects and to the side effects (dyspnea) of ticagrelor in patients with an acute myocardial infarction. In the current research proposal, we aim to investigate whether ticagrelor increases adenosine receptor stimulation in humans in vivo by ENT inhibition.

Conditions

  • Healthy

Interventions

DRUG

Ticagrelor 180 mg single dose

DRUG

Placebo

Sponsors & Collaborators

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • N. Riksen, MD, PhD · Radboud University Medical Center

  • G. Rongen, MD, PhD · Radboud University Medical Center

  • M. Gomes, MD, PhD · Dept Cardiology, Canisius Wilhelmina Hospital Nijmegen

  • S. El Messaoudi, MD · Radboud University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2013-11-30
Completion
2013-12-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01996735 on ClinicalTrials.gov